Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds.

Wang E, Sorolla MA, Krishnan PDG, Sorolla A.

Biomolecules. 2020 Feb 6;10(2). pii: E248. doi: 10.3390/biom10020248. Review.

2.

Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition.

Wang E, Sorolla A.

J Gynecol Oncol. 2019 Nov 5. doi: 10.3802/jgo.2020.31.e29. [Epub ahead of print]

3.

Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.

Sorolla A, Wang E, Golden E, Duffy C, Henriques ST, Redfern AD, Blancafort P.

Oncogene. 2020 Feb;39(6):1167-1184. doi: 10.1038/s41388-019-1056-3. Epub 2019 Oct 21. Review.

4.

Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers.

Kretzmann JA, Evans CW, Moses C, Sorolla A, Kretzmann AL, Wang E, Ho D, Hackett MJ, Dessauvagie BF, Smith NM, Redfern AD, Waryah C, Norret M, Iyer KS, Blancafort P.

Chem Sci. 2019 Jun 27;10(33):7718-7727. doi: 10.1039/c9sc01432b. eCollection 2019 Sep 7.

5.

Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides.

Sorolla A, Wang E, Clemons TD, Evans CW, Plani-Lam JH, Golden E, Dessauvagie B, Redfern AD, Swaminathan-Iyer K, Blancafort P.

Nanomedicine. 2019 Aug;20:102003. doi: 10.1016/j.nano.2019.04.006. Epub 2019 May 2.

6.

Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy.

Clemons TD, Singh R, Sorolla A, Chaudhari N, Hubbard A, Iyer KS.

Langmuir. 2018 Dec 18;34(50):15343-15349. doi: 10.1021/acs.langmuir.8b02946. Epub 2018 Nov 27.

PMID:
30441895
7.

Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells.

Shrestha S, Sorolla A, Fromont J, Blancafort P, Flematti GR.

Mar Drugs. 2018 Oct 1;16(10). pii: E361. doi: 10.3390/md16100361.

8.

Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.

Wang E, Sorolla A, Cunningham PT, Bogdawa HM, Beck S, Golden E, Dewhurst RE, Florez L, Cruickshank MN, Hoffmann K, Hopkins RM, Kim J, Woo AJ, Watt PM, Blancafort P.

Oncogene. 2019 Jan;38(1):140-150. doi: 10.1038/s41388-018-0421-y. Epub 2018 Aug 3.

9.

Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells.

Shrestha S, Sorolla A, Fromont J, Blancafort P, Flematti GR.

Mar Drugs. 2018 Feb 8;16(2). pii: E53. doi: 10.3390/md16020053.

10.

Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.

Garcia-Bloj B, Moses C, Sgro A, Plani-Lam J, Arooj M, Duffy C, Thiruvengadam S, Sorolla A, Rashwan R, Mancera RL, Leisewitz A, Swift-Scanlan T, Corvalan AH, Blancafort P.

Oncotarget. 2016 Sep 13;7(37):60535-60554. doi: 10.18632/oncotarget.11142.

11.

ATF2 alters melanocyte response and macrophage recruitment in UV-irradiated neonatal mouse skin.

Senft D, Sorolla A, Dewing A, Claps G, Lau E, Walker GJ, Ronai ZA.

Pigment Cell Melanoma Res. 2015 Jul;28(4):481-4. doi: 10.1111/pcmr.12382. Epub 2015 May 30. No abstract available.

12.

Identification of novel hypomorphic and null mutations in Klf1 derived from a genetic screen for modifiers of α-globin transgene variegation.

Sorolla A, Tallack MR, Oey H, Harten SK, Daxinger LC, Magor GW, Combes AN, Ilsley M, Whitelaw E, Perkins AC.

Genomics. 2015 Feb;105(2):116-22. doi: 10.1016/j.ygeno.2014.09.013. Epub 2014 Oct 31.

13.

An ENU mutagenesis screen identifies novel and known genes involved in epigenetic processes in the mouse.

Daxinger L, Harten SK, Oey H, Epp T, Isbel L, Huang E, Whitelaw N, Apedaile A, Sorolla A, Yong J, Bharti V, Sutton J, Ashe A, Pang Z, Wallace N, Gerhardt DJ, Blewitt ME, Jeddeloh JA, Whitelaw E.

Genome Biol. 2013;14(9):R96.

14.

Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.

Sorolla A, Yeramian A, Valls J, Dolcet X, Bergadà L, Llombart-Cussac A, Martí RM, Matias-Guiu X.

Mol Oncol. 2012 Oct;6(5):530-41. doi: 10.1016/j.molonc.2012.06.006. Epub 2012 Jul 7.

15.

Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner.

Yeramian A, Santacana M, Sorolla A, Llobet D, Encinas M, Velasco A, Bahi N, Eritja N, Domingo M, Oliva E, Dolcet X, Matias-Guiu X.

Lab Invest. 2011 Jun;91(6):859-71. doi: 10.1038/labinvest.2011.58. Epub 2011 May 2.

16.

Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.

Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Martí RM.

Int J Cancer. 2012 Feb 15;130(4):967-78. doi: 10.1002/ijc.26096. Epub 2011 Jun 18.

17.

A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma.

Pallares J, Santacana M, Puente S, Lopez S, Yeramian A, Eritja N, Sorolla A, Llobet D, Dolcet X, Matias-Guiu X.

Anal Quant Cytol Histol. 2009 Aug;31(4):217-26. Review.

PMID:
19736869
18.

Targeted therapies in gynecologic cancers and melanoma.

Ortega E, Marti RM, Yeramian A, Sorolla A, Dolcet X, Llobet D, Abal L, Santacana M, Pallares J, Llombart-Cussac A, Matias-Guiu X.

Semin Diagn Pathol. 2008 Nov;25(4):262-73. Review.

PMID:
19013892
19.

Loss of heterozygosity in endometrial carcinoma.

Velasco A, Pallares J, Santacana M, Yeramian A, Dolcet X, Eritja N, Puente S, Sorolla A, Llecha N, Matias-Guiu X.

Int J Gynecol Pathol. 2008 Jul;27(3):305-17. doi: 10.1097/PGP.0b013e31815daf1a. Review.

PMID:
18580307
20.

Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.

Llobet D, Eritja N, Encinas M, Sorolla A, Yeramian A, Schoenenberger JA, Llombart-Cussac A, Marti RM, Matias-Guiu X, Dolcet X.

Anticancer Drugs. 2008 Feb;19(2):115-24. doi: 10.1097/CAD.0b013e3282f24031.

PMID:
18176107

Supplemental Content

Loading ...
Support Center